US EditionPublished • loading... • Updated
Fenebrutinib Hits Key Phase 3 Marks in Relapsing and Primary Progressive MS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Summary by neurologylive.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Fenebrutinib Hits Key Phase 3 Marks in Relapsing and Primary Progressive MS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Findings from a second phase 3 trial, dubbed FENhance 1, assessing fenebrutinib in patients with relapsing multiple sclerosis are anticipated by the first half of 2026.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
